The stock of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) is a huge mover today! About 330,601 shares traded hands or 17.47% up from the average. Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) has risen 83.70% since April 27, 2016 and is uptrending. It has outperformed by 78.47% the S&P500.
The move comes after 8 months negative chart setup for the $501.57 million company. It was reported on Nov, 30 by Barchart.com. We have $17.65 PT which if reached, will make NASDAQ:BLCM worth $15.05 million less.
Analysts await Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) to report earnings on March, 13. They expect $-0.61 EPS, up 3.17% or $0.02 from last year’s $-0.63 per share. After $-0.66 actual EPS reported by Bellicum Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -7.58% EPS growth.
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) Ratings Coverage
Out of 7 analysts covering Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), 5 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 71% are positive. Bellicum Pharmaceuticals Inc has been the topic of 10 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Citigroup maintained Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) rating on Tuesday, August 9. Citigroup has “Neutral” rating and $24 price target. The firm has “Buy” rating by Jefferies given on Tuesday, August 9. The stock of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) earned “Neutral” rating by Citigroup on Thursday, February 25. The rating was downgraded by Zacks to “Hold” on Wednesday, August 19. The firm has “Buy” rating given on Friday, June 3 by SunTrust. Cantor Fitzgerald initiated the stock with “Buy” rating in Wednesday, November 2 report. Zacks downgraded Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) on Monday, September 21 to “Sell” rating. The rating was initiated by Suntrust Robinson with “Buy” on Friday, June 3. The rating was initiated by Citigroup on Friday, July 24 with “Buy”. The firm has “Buy” rating by Guggenheim given on Friday, September 11.
According to Zacks Investment Research, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas.”
More notable recent Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) news were published by: Marketwatch.com which released: “Bellicum Pharmaceuticals upgraded to buy from neutral at Citigroup” on December 18, 2014, also Fool.com with their article: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Juno Therapeutics, Inc.” published on June 26, 2016, Fool.com published: “Better Buy: Agenus Inc. vs. Bellicum Pharmaceuticals Inc.” on October 18, 2016. More interesting news about Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) were released by: Fool.com and their article: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Celldex Therapeutics” published on August 03, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Bellicum Pharmaceuticals Inc.BLCM” with publication date: December 13, 2014.
BLCM Company Profile
Bellicum Pharmaceuticals, Inc., incorporated on July 14, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Firm uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Firm is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. The Company’s CID technologies include CaspaCIDe, CIDeCAR and GoCAR-T.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.